Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom
You may not be if
Active central nervous system (CNS) involvement unless clinically stable
History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
History of solid organ or hematologic stem cell transplantation
Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug
Clareo Health | A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors
